IP Library › Granted Patent US 8,486,924
Granted Patent B2
US 8,486,924 · App. 12/741,954 · Granted Jul 16, 2013

Taxane delivery system

Inventors: Steven M. Ansell (Princeton, NJ); Sharon Johnstone (Princeton, NJ); Paul Tardi (Princeton, NJ); Lawrence Mayer (Princeton, NJ)
Assignee: Celator Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,486,924
App. No.
12/741,954
Granted
Jul 16, 2013
Kind
B2
Abstract

Nanoparticulate formulations for delivery of taxane conjugate prodrug formed from a taxane coupled to a hydrophobic moiety through a glycolate linker are described.

Claims (16)

1. A pharmaceutical taxane composition which comprises nanoparticles or micelles wherein said micelles or nanoparticles are formed from noncovalently associating a conjugate of a taxane covalently coupled to a hydrophobic molecule through a diglycolate linker with a lipid and/or an amphiphilic stabilizer.

2. The composition of claim 1 wherein said conjugate is associated with a lipid and an amphiphilic stabilizer.

3. The composition of claim 2 wherein the lipid is a phospholipid and the amphiphilic stabilizer is a copolymer.

4. The composition of claim 3 wherein said copolymer is a copolymer of polyethylene glycol and polystyrene.

5. The composition of claim 4 which further contains an additional antineoplastic agent formulated to mimic the pharmacokinetics of the taxane composition.

6. A method to administer a taxane to a subject which method comprises administering to said subject the composition of claim 2 .

7. The method of claim 6 which further comprises administering an additional antineoplastic agent formulated to mimic the pharmacokinetics of the taxane composition.

8. The composition of claim 1 wherein the taxane is paclitaxel or docetaxel.

9. The composition of claim 1 wherein the hydrophobic moiety is a long-chain alcohol, a tocopherol, or a steroid.

10. The composition of claim 1 wherein the lipid is a phospholipid or a tocopherol.

11. The composition of claim 1 wherein the amphiphilic stabilizer is a copolymer.

12. The composition of claim 11 wherein said copolymer is a copolymer of polyethylene glycol and polystyrene.

13. The composition of claim 1 which further contains an additional antineoplastic agent formulated to mimic the pharmacokinetics of the taxane composition.

14. A method to administer a taxane to a subject which method comprises administering to said subject the composition of claim 1 .

15. The method of claim 14 which further comprises administering an additional antineoplastic agent formulated to mimic the pharmacokinetics of the taxane composition.

16. A method to prepare the composition of claim 1 which method comprises rapidly mixing water and a miscible solvent containing said conjugate, lipid, and/or amphiphilic stabilizer in a confined space using controlled flow rates.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded May 5, 2021
From: BANK OF AMERICA, N.A.
To: JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS INTERNATIONAL LIMITED; JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED; CELATOR PHARMACEUTICALS, INC.; CAVION, INC.
Reel/Frame 056150/0708 →
SECURITY AGREEMENT Recorded May 5, 2021
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056151/0010 →
SECURITY AGREEMENT Recorded Jul 12, 2016
From: CELATOR PHARMACEUTICALS, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 039312/0397 →
RELEASE OF SECURITY INTEREST Recorded Jun 15, 2012
From: THOMAS, MCNERNEY & PARTNERS II, L.P.; TMP NOMINEE II, LLC; TMP ASSOCIATES II, L.P.; DOMAIN PARTNERS VI, L.P.; VENTURES WEST 7 LIMITED PARTNERSHIP; VENTURES WEST 7 U.S. LIMITED PARTNERSHIP; WORKING OPPORTUNITY FUND (EVCC) LTD.; BDC CAPITAL INC.; QUAKER BIOVENTURES, L.P.; GARDEN STATE LIFE SCIENCES VENTURE FUND, L.P.
To: CELATOR PHARMACEUTICALS, INC.
Reel/Frame 028385/0371 →
SECURITY AGREEMENT Recorded Dec 20, 2011
From: CELATOR PHARMACEUTICALS, INC.
To: BDC CAPITAL INC.; DOMAIN PARTNERS VI, L.P.; GARDEN STATE LIFE SCIENCES VENTURE FUND, L.P.; QUAKER BIOVENTURES, L.P.; THOMAS, MCNERNEY & PARTNERS II, L.P.; TMP ASSOCIATES II, L.P.; TMP NOMINEE II, LLC; VENTURES WEST 7 LIMITED PARTNERSHIP; VENTURES WEST 7 U.S. LIMITED PARTNERSHIP; WORKING OPPORTUNITY FUND (EVCC) LTD.
Reel/Frame 027423/0058 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2010
From: ANSELL, STEVEN M.; JOHNSTONE, SHARON; TARDI, PAUL; MAYER, LAWRENCE
To: CELATOR PHARMACEUTICALS, INC.
Reel/Frame 024977/0548 →
Continuity (2)
Provisional Application 60990907 · Nov 28, 2007
Related Publication 20100331290A1 · Dec 30, 2010